Elad Naggar / Chairman
Mr. Elad Naggar has diverse experience in the life science industry as the CEO of start-up/operating companies as well as an investment manager. He has previously served as the CEO of multiple medical device companies such as IBI Medical Ltd., Radiancy Ltd. and Mindguard Ltd. (GM). Elad has an LLB and MBA (Magna Cum Laude) from Tel Aviv University and is an honors graduate of the Wharton School of Business Global Consulting Practicum.
Dr. David M. Milch / Director
Dr. Milch is a 1980 graduate of Harvard Medical School, having completed his undergraduate studies in biology at Stanford University in 1976. Upon finishing his clinical and research responsibilities in 1984, Dr. Milch moved to New York City to pursue a business career. Between 1980 and 1989 Dr. Milch has been a principal of Bermil Industries, a closely held corporation controlled by the Milch Family, involved with capital equipment manufacture and distribution, financing, real estate development, and other entrepreneurial activities. After a portion of Bermil was sold to a public company in 1989, Dr. Milch turned a significant portion of his time and attention to venture investments in technology and the life sciences. Dr. Milch and his associates have invested in or advised on a wide variety opportunities including The American Blood Institute (private sale), Intelligent Medical Imaging (IPO), Biofield (IPO), Nitinol (IPO), Datatec Systems (reverse merger), Warp Technologies (reverse merger), MiniMed (bought by Medtronic), Advanced Bionics (bought by Boston Scientific), Theravance (IPO), and others. Recently his activity has focused on medical device companies from Israel.
Tomer Kariv / Director
Mr. Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies. Mr. Kariv serves as an active board member of many of the funds' portfolio companies, assuming a special responsibility for strategic planning. Among others, Mr. Kariv serves as the Chairman of Check-Cap Ltd and is a board member of Macrocure Ltd, Arno Therapeutics Inc. and Aposense Ltd. During the 10 years prior to establishing Pontifax, Mr. Kariv played a key role in investing, managing and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial institutions. Mr. Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Dr. Jacob Dagan / Director
Dr. Dagan has more than twenty five years of experience in management, operations, sales, finance, organizational planning and business development in the medical services and device sectors for public and private companies in the US and Israel. Since the beginning of 2011, responsible for Life Science investments at Migdal Capital Markets- Underwriting and Business Initiative Company. Since 2005 partner in ProMed Capital, LLC. Held the position of Director of BioMedical Engineering of the Sheeba Medical Center and Associate Professor of Bio-Medical Engineering at Tel Aviv University. For seven years held senior management positions with Sharplan Lasers,. Dr. Dagan has been Involved in fund raising and strategy consulting to Bio-Medical, Bio-Technology companies and on the Board or in operating responsibilities of several start-ups, including Biofield Corp. (CEO), Heart-Guard, Inc. (CEO) and more. Dr. Dagan received his Doctorate from Columbia University, a MSc in Nuclear Sciences from the Technion and a B.Sc. in Mechanical and Nuclear Engineering from the Technion, Israel Inst. of Technology.
Dr. Ehud Geller / Director
Dr. Ehud Geller co-founded Medica Venture Partners in 1995. He brings over 30 years of senior executive operational experience in healthcare companies, both in the U.S. and Israel. From 1985 to 1990, Dr. Geller served as the President and CEO of Interpharm Laboratories, Ltd. and was instrumental in bringing this publicly traded company to a market capitalization of over $380 million, with its leading product, REBIF, a product whose revenues ultimately reached $2 billion. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva and Executive VP of the Teva Group, the world’s largest generic pharmaceutical company. At Teva, he led the acquisition of Ikapharm Ltd. and formulated the company’s successful strategy for entry into the U.S. market. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange (TASE). Dr. Geller began his industry career at Wyeth Laboratories in the U.S., where he spent seven years with responsibilities ranging from pharmaceutical research through pilot plant operations and corporate new product introduction management. Dr. Geller has a B.Sc. in chemical engineering, an MBA from Columbia University/Drexel Institute and a Ph.D. in pharmaceutical/chemical engineering from Drexel Institute, Philadelphia.
Ms. Efrat Romano is the CFO of Biomedix. She has vast experience in financial management, accounting, tax and legal issues. Prior to joining Biomedix, Efrat served as a Manager in PriceWaterhouseCoopers Israel, where she led audit teams and handled publicly-traded as well as privately owned companies. Efrat is a CPA and holds a B.A. in Accounting and Economy from the Ben-Gurion University in Israel.
Meni Mor / Director
Mr. Meni Mor serves as a board member in Allium Medical Solution since March 2010. Mr. Mor also serves as the chairman of the board of directors of Biomedix Incubator Ltd. (TASE:BMDX) , one of Allium's largest shareholders and a board member in D. Medical Industries (TASE:DMED) , D.N.A. Biomedical Solutions Ltd. (TASE:DNA) and other private companies as well.
Ms. Shimrit Wharshavsky
Ms. Yehudit Koren